Gilead Sciences (NASDAQ:GILD) Earns Hold Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Friday morning, Benzinga reports.

Other analysts also recently issued reports about the company. StockNews.com downgraded Gilead Sciences from a strong-buy rating to a buy rating in a research report on Friday, April 19th. Royal Bank of Canada decreased their price objective on Gilead Sciences from $76.00 to $75.00 and set a sector perform rating for the company in a report on Wednesday, February 14th. Mizuho dropped their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a buy rating on the stock in a report on Thursday, February 22nd. Oppenheimer reiterated an outperform rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. Finally, Truist Financial cut shares of Gilead Sciences from a buy rating to a hold rating and dropped their price target for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of Hold and an average target price of $83.87.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $65.42 on Friday. The company has a market capitalization of $81.45 billion, a P/E ratio of 181.72, a price-to-earnings-growth ratio of 1.17 and a beta of 0.19. The company’s 50-day moving average is $71.28 and its 200 day moving average is $76.25. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences has a fifty-two week low of $64.63 and a fifty-two week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the previous year, the company earned $1.37 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences will post 3.82 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.71%. Gilead Sciences’s payout ratio is currently 855.56%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Altfest L J & Co. Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter worth $210,000. Federated Hermes Inc. raised its position in Gilead Sciences by 4.9% during the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after purchasing an additional 175,925 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new stake in Gilead Sciences during the fourth quarter worth about $74,000. Abundance Wealth Counselors purchased a new position in shares of Gilead Sciences in the 3rd quarter worth about $1,881,000. Finally, HTLF Bank bought a new position in shares of Gilead Sciences during the 4th quarter valued at about $253,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.